ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1028

Impact of the Kidney Allocation System (KAS) in Highly Sensitized Patients

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Kumar, Vineeta, University of Alabama at Birmingham , Birmingham, Alabama, United States
  • Locke, Jayme E., University of Alabama at Birmingham , Birmingham, Alabama, United States
  • Gaston, Robert S., University of Alabama at Birmingham , Birmingham, Alabama, United States

Highly sensitized (HS) patients, defined as a PRA of 99-100% are awarded additional priority points in the new KAS instituted December 2014. We evaluated the impact of these changes at our institution at 1 and 2 year post transplantation


HS candidates who received a transplant on or after 12/4/2014 were prospectively monitored. Treatment included induction with anti-thymocyte globulin & IV corticosteroids, maintenance with tacrolimus, mycophenolate & prednisone. Designated care providers followed the HS recipients with more intensive frequency, donor specific anti HLA antibody (DSA) & viral monitoring, implantation & 6 month surveillance biopsies. Outcomes of interest were rate of transplantation, patient & allograft survival and function, acute cellular or antibody mediated rejection (AbMR). and were compared in a matched control population in a 1:2 fashion for age, race, and time of transplant.


There were 15 HS patients transplanted between 12/8/14-10/5/15. The rate of transplant has risen from 1.6% in 2012 to 12.6% in 2015.60% of these were from national offers in contrast to 37.5% in the past. All 15 recipients have >1 year follow up time with 100% patient & graft survival. 12 out of 15 have 2 year follow up time with 2 graft losses (for recurrent FSGS) and 1 death for sepsis in this group. Rate of patient and graft survial in the matched cohort was 100% at 1 & 2 years post transplant. Graft function was equivalent in the two groups with serum creatinine (1.4vs.1.6mg/dl, Pvalue 0.7), eGFR (52vs.48ml/min/m2, pvalue 0.9), random urine protein/creatinine ratio (1.1vs.2.3). Rate of denovo DSA formation at 2 years was similar in the two groups at 23vs.26%, p value 0.1. All the high PRA patients in this study were followed by a specialized team with an average of 16 clinic visits per patient vs. 9 in the control population


There has been a shift to increased national offers under the new KAS within the HS candidates at our institution as was intended by the new KAS. All of them have had acceptable early patient and allograft survival and function with intensive and individualized monitoring and follow up. However care of these patients is very resource itensive and needs a dedicated and specialized group of care givers for post transplant care for a successful outcome that benefits a very specific subset of patients.